Orodispersible films containing ball milled aripiprazole-poloxamer®407 solid dispersions.
Aripiprazole
Ball milling
Disintegration time
Orodispersible films
Poloxamer®407
Tribology
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
15 Feb 2020
15 Feb 2020
Historique:
received:
21
08
2019
revised:
25
11
2019
accepted:
11
12
2019
pubmed:
18
12
2019
medline:
25
11
2020
entrez:
18
12
2019
Statut:
ppublish
Résumé
This research aimed at developing ODFs containing an antipsychotic drug - aripiprazole (ARP). ARP, as a BCS II class molecule, requires enhancing its water solubility prior to formulating. Therefore, a solid dispersion of ARP - Poloxamer® 407 was prepared by ball milling, then incorporated into the films. It was found that co-processing led to an over 100-fold increase in drug solubility in comparison with pure drug. Moreover, ODFs with solid dispersion showed faster drug release (>95% below 15 min) and disintegration (<30 s), compared with raw ARP films. These results are believed to be due to the solubilization effect of poloxamer and enhanced wettability of the film. Films containing solid dispersions were found to possess smoother film surfaces and favorable mechanical properties - flexibility and strength. The ODF formulations, prepared by a casting method, were based on three different polymers (Kollicoat® IR, Kollicoat® Protect or PVA). It was found that not only the form of the incorporated drug, but also the type of film-forming polymer had an impact on the analyzed parameters. The use of PVA was beneficial in the film formulation with aripiprazole in comparison to other tested film-forming polymers.
Identifiants
pubmed: 31843552
pii: S0378-5173(19)31000-2
doi: 10.1016/j.ijpharm.2019.118955
pii:
doi:
Substances chimiques
Polyvinyls
0
Poloxamer
106392-12-5
Aripiprazole
82VFR53I78
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118955Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.